InMed Pharmaceuticals (IN) Stock Price, News & Analysis

Company Overview

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: C$4.19 to C$4.19
• 52-Week Range: N/A
• Volume: 17,035 shs
• Average Volume: 29,552 shs
• Market Capitalization: C$33.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IN Stock Analysis - Frequently Asked Questions

How do I buy shares of InMed Pharmaceuticals?

Shares of IN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of InMed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that InMed Pharmaceuticals investors own include Gladstone Land (LAND), Baidu (BIDU), Comstock Resources (CRK), Editas Medicine (EDIT), Enovix (ENVX), HEXO (HEXO) and Merck & Co., Inc. (MRK).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Computer Hardware
• Current Symbol: TSE:IN
• CUSIP: N/A
• CIK: N/A
• Web: www.inmedpharma.com
• Phone: 604-669-7207
• Fax: N/A
• Employees: 12
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 8.48
• Current Ratio: 2.13
• Quick Ratio: 1.45

Sales & Book Value

• Annual Sales: C$574,677.00
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 10.40
• Book Value: C$0.76 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 8,051,000
• Free Float: N/A
• Market Cap: C$33.73 million
• Optionable: Not Optionable
• Beta: N/A